IMPEDIMED LIMITED — Capital/Financing Update 2016

Mar 21, 2016

==> picture [193 x 43] intentionally omitted <==

22 March 2016

ASX ANNOUNCEMENT

Completion of Private Placement and SPP

Brisbane, Australia, Carlsbad, California, 22 March, 2016 – ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, is pleased to announce that following shareholder approval being granted at an Extraordinary General Meeting held on 15 March 2016, the issue of 34,884,513 new shares in the 2[nd] Tranche of the $75 Million Private Placement has now been successfully completed.

In addition, the Shareholder Purchase Plan (SPP), which opened on 25 February 2016, for existing shareholders, raised a further A$74,128.50. A total of 78,030 new shares will be issued at an issue price of A$0.95. As advised in the SPP documentation, the allotment date for these shares is 23 March 2016.

• ENDS -

For further information contact: Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Kyahn Williamson, Buchan Investor and Media Relations T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.